Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling

Cisplatin-induced acute kidney injury (AKI) is a major complication of chemotherapy, and effective protective strategies remain limited. This study aimed to investigate the renoprotective effects of ginsenoside Rh3 and explore the potential involvement of JAK2/STAT3 signaling in its protective mechanisms. First, network pharmacology, protein–protein interaction analysis, molecular docking, and molecular dynamics simulations were performed to identify potential targets and signaling pathways associated with Rh3. Subsequently, the protective effects of Rh3 were evaluated in a mouse model of cisplatin-induced AKI and in cisplatin-treated HK-2 cells. Cellular thermal shift assay (CETSA) and JAK2 overexpression experiments were further conducted to investigate the involvement of JAK2-associated signaling. Rh3 treatment alleviated cisplatin-induced renal dysfunction and histopathological damage in mice, as evidenced by improvements in serum creatinine, blood urea nitrogen, and renal injury markers. In HK-2 cells, Rh3 improved cell viability and reduced cell death, intracellular reactive oxygen species (ROS) accumulation, and apoptosis-associated protein expression. Furthermore, Rh3 improved oxidative stress-related indicators, including glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA), and reduced the mRNA expression of interleukin-1β (IL-1β) and interleukin-6 (IL-6). Network pharmacology and molecular docking analyses identified JAK2 as a potential candidate target. CETSA demonstrated increased thermal stability of JAK2 following Rh3 treatment, while JAK2 overexpression partially reversed the protective effects of Rh3 on cell viability, ROS accumulation, and inflammatory marker expression. Rh3 treatment was also associated with reduced phosphorylation of JAK2 and STAT3. Collectively, these findings demonstrate the protective effects of ginsenoside Rh3 against cisplatin-induced AKI and suggest that modulation of JAK2/STAT3-associated signaling may contribute to its renoprotective effects.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.2013484
Primary Topic
Chemotherapy-induced organ toxicity mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling

Qunying Feng, Yangyang Guo, Liangchen Qu, Tingting Chen et al.
2 links
Frontiers in Pharmacology
Chemotherapy-induced organ toxicity mitigation
article

Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling

Qunying Feng, Yangyang Guo, Liangchen Qu, Tingting Chen, Hengyue Zhu, Linghui Zheng, Xiangqiong Zheng, Siqi Cao
article en

Abstract

Cisplatin-induced acute kidney injury (AKI) is a major complication of chemotherapy, and effective protective strategies remain limited. This study aimed to investigate the renoprotective effects of ginsenoside Rh3 and explore the potential involvement of JAK2/STAT3 signaling in its protective mechanisms. First, network pharmacology, protein–protein interaction analysis, molecular docking, and molecular dynamics simulations were performed to identify potential targets and signaling pathways associated with Rh3. Subsequently, the protective effects of Rh3 were evaluated in a mouse model of cisplatin-induced AKI and in cisplatin-treated HK-2 cells. Cellular thermal shift assay (CETSA) and JAK2 overexpression experiments were further conducted to investigate the involvement of JAK2-associated signaling. Rh3 treatment alleviated cisplatin-induced renal dysfunction and histopathological damage in mice, as evidenced by improvements in serum creatinine, blood urea nitrogen, and renal injury markers. In HK-2 cells, Rh3 improved cell viability and reduced cell death, intracellular reactive oxygen species (ROS) accumulation, and apoptosis-associated protein expression. Furthermore, Rh3 improved oxidative stress-related indicators, including glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA), and reduced the mRNA expression of interleukin-1β (IL-1β) and interleukin-6 (IL-6). Network pharmacology and molecular docking analyses identified JAK2 as a potential candidate target. CETSA demonstrated increased thermal stability of JAK2 following Rh3 treatment, while JAK2 overexpression partially reversed the protective effects of Rh3 on cell viability, ROS accumulation, and inflammatory marker expression. Rh3 treatment was also associated with reduced phosphorylation of JAK2 and STAT3. Collectively, these findings demonstrate the protective effects of ginsenoside Rh3 against cisplatin-induced AKI and suggest that modulation of JAK2/STAT3-associated signaling may contribute to its renoprotective effects.

Frontiers in PharmacologyVol. 17
Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Zhejiang Taizhou Hospital (CN)
Good health and well-being
Chemotherapy-induced organ toxicity mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon